Initial Experience of Bioabsorbable Polymer Everolimus-Eluting Synergy Stents in High-Risk Patients Undergoing Complex PCI With Early Discontinuation of Dual-Antiplatelet Therapy

Sponsored by Boston Scientific

As more elderly and co-morbid patients require percutaneous revascularization, 1 year of dual-antiplatelet therapy (DAPT) becomes concerning. This study assessed those in our unit who underwent percutaneous coronary intervention (PCI) with a Synergy stent to examine a minimum of 6 months of clinical outcomes after early discontinuation of DAPT.

Initial experience of bioabsorbable polymer everolimus-eluting Synergy stents in high-risk patients undergoing complex percutaneous coronary intervention with early discontinuation of dual-antiplatelet therapy

Download and read the full paper

(J INVASIVE CARDIOL Epub 2016 December 15)


With an unrestricted educational grant from Boston Scientific


Rebecca L. Noad, MB, PhD; Colm G. Hanratty, MD; Simon J. Walsh, MD


This case report does not reflect the opinion of PCR or PCRonline, nor does it engage their responsibility.